Navigation Links
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Date:11/30/2007

WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed enrollment of patients in the ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase III trials for the investigational once-daily oral anti-cancer drug vandetanib. Data from the study is expected in 2008.

ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line anti-cancer therapy.

"Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

-- ZODIAC (vandetanib + docetaxel versus docetaxel alone)

-- ZEAL (vandetanib + pemetrexed versus placebo + pemetrexed); and,

-- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo + BSC).

These studies are currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). (1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this indication.

About AstraZeneca

AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one of the world's leading pharmaceutical companies with health care sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion health care business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over three billion in savings to more than one million patients throughout the U.S. and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com

ZACTIMA is a registered trademark of the AstraZeneca group of companies.

(1) Natale RB et al. ZD6474 versus gefitinib in patients with advanced

NSCLC: Final results from two-part, double-blind randomized phase II

trial. Journal of Clinical Oncology, Vol 24, No 18S, 2006: 7000.

(2) Heymach JV et al. Randomized, Placebo-Controlled Phase II Study of

Vandetanib Plus Docetaxel in Previously Treated Non-Small-Cell Lung

Cancer Journal of Clinical Oncology, Vol 25, No 27, 2007: 4270-4277.


'/>"/>
SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 According to market ... and Demand Forecast to 2022 - Industry Insights by Slice ... Center and Others)" by P&S Market Research, the global ... 2015, and it is expected to grow at a CAGR ... slice type segment is expected to witness the faster growth, ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... KANSAS CITY, Mo. , May 3, 2016 ... of Kansas Medical Center,s Institute for Advancing Medical ... develop and commercialize new drugs, diagnostics and medical ... organizations provides BioNovus Innovations with rights to license, ... "This partnership ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Somnoware Healthcare Systems ... announced it has secured $9 million in Series A funding led by TransLink ... will be used by Somnoware to further fulfill its mission to connect, organize ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Quaker Ridge Golf Club in Scarsdale, New York on May 23, 2016 for ...
(Date:5/4/2016)... Palm City, Florida (PRWEB) , ... May 04, ... ... providers of cold therapy products, announced today the introduction of the innovative newly ... for post operative hip replacement patients. The plush design enhances comfort and enables ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy (CAET) ... promotion, time saving and planning tools to attendees and exhibitors for the 2016 ...
Breaking Medicine News(10 mins):